Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Int J Clin Pharmacol Ther ; 62(1): 48-55, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37942926

RESUMO

Adverse lamotrigine effects are more likely with concomitant use of antiepileptic drugs, rapid dose titration, and multiple drug use, highlighting the importance of measuring its concentration. Here, lamotrigine was administered the day after the third mRNA vaccination to a 20-year-old bipolar woman with these risk factors. Leukopenia occurred on day 12 without rapid concentration increase, but leukocytes gradually recovered after 22 weeks without discontinuation of lamotrigine. The second mRNA vaccination did not induce leukopenia. Possibly, a synergetic immune response to simultaneous vaccination and lamotrigine caused leukopenia, which recovered as the response weakened. Lamotrigine initiation immediately after mRNA vaccination may be a leukopenia risk factor.


Assuntos
COVID-19 , Leucopenia , Trombocitopenia , Feminino , Humanos , Adulto Jovem , Adulto , Lamotrigina/efeitos adversos , Anticonvulsivantes/efeitos adversos , Triazinas/efeitos adversos , COVID-19/prevenção & controle , Leucopenia/induzido quimicamente , Leucopenia/diagnóstico , Leucopenia/tratamento farmacológico , Trombocitopenia/tratamento farmacológico , RNA Mensageiro
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...